cas 40794-04-5|| where to buy 4-Chloro-2-methoxy-1-methylbenzene

Produktname:4-Chloro-2-methoxy-1-methylbenzene

IUPAC Name:4-chloro-2-methoxy-1-methylbenzene

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM283380-5g	in stock	ŮŮ
CM283380-10g	in stock	ħƴǸ
CM283380-25g	in stock	ħǪŌ
CM283380-100g	in stock	ŮħǙ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 40794-04-5 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:40794-04-5; Molekulare Formel:C8H9ClO; Schmelzpunkt:-; SMILES-Code:CC1=CC=C(Cl)C=C1OC; Dichte:

: Katalognummer:CM283380; Molekulargewicht:156.61; Siedepunkt:204°C at 760 mmHg; Mdl-Nr.:MFCD07368289; Lagerung:Store at 2-8°C.

: Crinecerfont; The New England Journal of Medicine publishes the primary CAHtalyst™ Adult Phase 3 study results of Crinecerfont for the treatment of congenital adrenal hyperplasia (CAH). Classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) is a rare genetic disorder, affected by a lack of cortisol and/or aldosterone. Corticotropin-releasing factor type 1 receptor (CRF1) antagonism is shown to clinically decrease ACTH production and adrenal androgen levels.
Neurocrine's Crinecerfont is an investigational, selective CRF1 antagonist being developed to reduce and control excess adrenocorticotropic hormone (ACTH) and adrenal androgens. The phase 3 study meets primary and important key secondary endpoints, including a significant reduction in androstenedione levels and lowering glucocorticoid dosing.